Profile Of Patients With Advanced Parkinson’s disease Suitable For Device-Aided Therapies: Restrospective Data Of A Large Cohort Of Romanian Patients

References

• Odin P, Ray Chaudhuri K, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015;21(10):1133–1144. doi:10.1016/j.parkreldis.2015.07.02026233582
   PubMed Web of Science ®Google Scholar
• Titova N, Martinez-Martin P, Katunina E, Chaudhuri KR. Advanced Parkinson’s or “complex phase” Parkinson’s disease? Re-evaluation is needed. J Neural Transm. 2017;124(12):1529–1537. doi:10.1007/s00702-017-1799-329116411
   PubMed Web of Science ®Google Scholar
• Krüger R, Hilker R, Winkler C, et al. Advanced stages of PD: interventional therapies and related patient-centered care. J Neural Transm. 2016;123(1):31–43. doi:10.1007/s00702-015-1418-026138439
   PubMed Web of Science ®Google Scholar
• Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES. Consensus on the definition of advanced Parkinson’s disease: a neurologists-based delphi study (CEPA Study). Parkinsons Dis. 2017;2017. doi:10.1155/2017/4047392
   Web of Science ®Google Scholar
• Antonini A, Stoessl AJ, Kleinman LS, et al. Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson’s disease: a multi-country delphi-panel approach. Curr Med Res Opin. 2018;34(12):2063–2073. doi:10.1080/03007995.2018.150216530016901
   PubMed Web of Science ®Google Scholar
• Fabbri M, Coelho M, Abreu D, et al. Do patients with late-stage Parkinson’s disease still respond to levodopa? Parkinsonism Relat Disord. 2016;26:10–16. doi:10.1016/j.parkreldis.2016.02.02126972527
   PubMed Web of Science ®Google Scholar
• Szász JA, Constantin VA, Orbán-Kis K, et al. Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: data from 107 tested patients. Mov Disord. 2018;33:171.
   Web of Science ®Google Scholar
• Szász JA, Szatmári S, Constantin V, et al. Characteristics of levodopa treatment in advanced Parkinson’s disease in the experiences of the neurology clinics of Târgu Mures, Romania. Orv Hetil. 2019;160(17):662–669. doi:10.1556/650.2019.3135431010306
   PubMed Web of Science ®Google Scholar
• Szász JA, Constantin V, Orbán-Kis K, et al. Dopamine agonists in advanced Parkinson’s disease: data from a large cohort of Romanian patients. J Parkinsons Dis. 2019;9(1):128. doi:10.3233/JPD-199900
   Google Scholar
• Van Rooden SM, Colas F, Martínez-Martín P, et al. Clinical subtypes of Parkinson’s disease. Mov Disord. 2011;26(1):51–58. doi:10.1002/mds.2334621322019
   PubMed Web of Science ®Google Scholar
• Rosqvist K, Horne M, Hagell P, Iwarsson S, Nilsson MH, Odin P. Levodopa effect and motor function in late stage Parkinson’s disease. J Parkinsons Dis. 2018;8(1):59–70. doi:10.3233/JPD-17118129480220
   PubMedGoogle Scholar
• Fasano A, Fung VSC, Lopiano L, et al. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol. 2019;19(1):1–11. doi:10.1186/s12883-019-1276-830606131
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–458. doi:10.1002/mds.109011391738
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa in Parkinson’s disease with motor fluctuations. Mov Disord. 2014;29(2):229–237. doi:10.1002/mds.2575124323641
   PubMed Web of Science ®Google Scholar
• Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease. Mov Disord. 2014;29(10):1273–1280. doi:10.1002/mds.2596125044402
   PubMed Web of Science ®Google Scholar
• Scott LJ. Opicapone: a review in Parkinson’s disease. Drugs. 2016;76(13):1293–1300. doi:10.1007/s40265-016-0623-y27498199
   PubMed Web of Science ®Google Scholar
• Patel AB, Jimenez-Shahed J. Profile of inhaled levodopa and its potential in the treatment of Parkinson’s disease: evidence to date. Neuropsychiatr Dis Treat. 2018;14:2955–2964. doi:10.2147/NDT.S14763330464480
   PubMed Web of Science ®Google Scholar
• Szász J, Constantin V, Fazakas P, et al. The role of selective monoamine oxidase B inhibitors in the therapeutic strategy of Parkinson’s disease in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital. Orv Hetil. 2017;158:2023–2028. doi:10.1556/650.2017.3091429250969
   PubMed Web of Science ®Google Scholar
• Rosa MM, Ferreira JJ, Coelho M, Freire R, Sampaio C. Prescribing patterns of antiparkinsonian agents in Europe. Mov Disord. 2010;25(8):1053–1060. doi:10.1002/mds.2303820222132
   PubMed Web of Science ®Google Scholar
• Morrish P. Prescribing in Parkinson’s disease: a story of hope and adverse events. Pract Neurol. 2012;12(5):335–340. doi:10.1136/practneurol-2012-00021022976066
   PubMedGoogle Scholar
• Osinaga EA, Inchaurregui LCA, Ikobaltzeta IE, Alonso NB, del Pozo JG. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque autonomous community (Spain) (1992–2004). Parkinsonism Relat Disord. 2007;13(8):500–504. doi:10.1016/j.parkreldis.2007.03.00417532251
   PubMed Web of Science ®Google Scholar
• Regidor I, Santos-Garciá D, Catalán MJ, et al. Impact of disease duration in effectiveness of treatment with levodopa-carbidopa intestinal gel and factors leading to discontinuation. J Parkinsons Dis. 2019;9(1):173–182. doi:10.3233/JPD-18132430562907
   PubMedGoogle Scholar
• Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):728–741. doi:10.1016/j.parkreldis.2009.09.00519805000
   PubMed Web of Science ®Google Scholar
• Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653. doi:10.1002/mds.2342921069833
   PubMed Web of Science ®Google Scholar
• Fülesdi B, Mitre C, Molnár C. Perioperative management of patients with Parkinson’s disease. Orv Hetil. 2015;156(34):1355–1359. doi:10.1556/650.2015.3023326278480
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Pirtosek Z, Pickut B, et al. Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: final long-term non-motor, quality of life and safety results from the GLORIA registry. Mov Disord. 2016;31(100):S661. doi:10.1002/mds.26688
   Google Scholar
• Antonini A, Poewe W, Chaudhuri KR, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord. 2017;45:13–20. doi:10.1016/j.parkreldis.2017.09.01829037498
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149. doi:10.1016/S1474-4422(13)70293-X24361112
   PubMed Web of Science ®Google Scholar
• Băjenaru O, Ene A, Popescu BO, et al. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson’s disease: a multicenter Romanian experience. J Neural Transm. 2016;123(4):407–414. doi:10.1007/s00702-015-1496-z26699635
   PubMed Web of Science ®Google Scholar
• Juhász A, Aschermann Z, Ács P, et al. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: an open-label study. Parkinsonism Relat Disord. 2017;37:79–86. doi:10.1016/j.parkreldis.2017.02.00128185758
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197–203. doi:10.3233/JPD-2011-1103723934921
   PubMedGoogle Scholar
• Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord. 2015;30(4):510–516. doi:10.1002/mds.2606725382161
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018;17(9):749–759. doi:10.1016/S1474-4422(18)30239-430055903
   PubMed Web of Science ®Google Scholar
• Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson’s disease. Mov Disord. 2019;34(3):353–365. doi:10.1002/mds.2762630719763
   PubMed Web of Science ®Google Scholar
• Möller JC, Körner Y, Dodel RC, et al. Pharmacotherapy of Parkinson’s disease in Germany. J Neurol. 2005;252(8):926–935. doi:10.1007/s00415-005-0784-115765268
   PubMed Web of Science ®Google Scholar
• Benbir G, Özekmekçi S, Apaydin H, Delil S, Erginöz E. A hospital-based study: risk factors in development of motor complications in 555 Parkinson’s patients on levodopa therapy. Clin Neurol Neurosurg. 2006;108(8):726–732. doi:10.1016/j.clineuro.2006.02.00216564615
   PubMed Web of Science ®Google Scholar
• Brun L, Lefaucheur R, Fetter D, et al. Non-motor fluctuations in Parkinson’s disease: prevalence, characteristics and management in a large cohort of parkinsonian outpatients. Clin Neurol Neurosurg. 2014;127:93–96. doi:10.1016/j.clineuro.2014.10.00625459250
   PubMed Web of Science ®Google Scholar
• Kadastik-Eerme L, Taba N, Asser T, Taba P. Factors associated with motor complications in Parkinson’s disease. Brain Behav. 2017;7(10):1–8. doi:10.1002/brb3.837
   Web of Science ®Google Scholar
• Szatmari S, Illigens BMW, Siepmann T, Pinter A, Takats A, Bereczki D. Neuropsychiatric symptoms in untreated parkinson’s disease. Neuropsychiatr Dis Treat. 2017;13:815–826. doi:10.2147/NDT.S13099728352181
   PubMed Web of Science ®Google Scholar
• Csóka M, Molnár S, Kellos É, Domján G. Problem solving care models of Parkinson’s disease introduction: Parkinson’s disease. Orv Hetil. 2016;157(22):855–868. doi:10.1556/650.2016.3047927211355
   PubMed Web of Science ®Google Scholar
• Hermanowicz N, Jones SA, Hauser RA. Impact of non-motor symptoms in Parkinson’s disease: a PMDAlliance survey. Neuropsychiatr Dis Treat. 2019;Volume 15:2205–2212. doi:10.2147/ndt.s213917
   Web of Science ®Google Scholar
• Zhang C, Zang Y, Song Q, et al. The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia. Neuropsychiatr Dis Treat. 2019;15:1639–1647. doi:10.2147/NDT.S17945331296990
   PubMed Web of Science ®Google Scholar
• Romosan A-M, Romosan R-S, Bredicean AC, Simu MA. Affective theory of mind in Parkinson’s disease: the effect of cognitive performance. Neuropsychiatr Dis Treat. 2019;15:2521–2535. doi:10.2147/NDT.S21928831564879
   PubMed Web of Science ®Google Scholar
• Szász JA, Orbán-Kis K, Constantin VA, et al. Therapeutic strategies in the early stages of Parkinson’s disease: a cross-sectional evaluation of 15 years’ experience with a large cohort of Romanian patients. Neuropsychiatr Dis Treat. 2019;15:831–838. doi:10.2147/NDT.S19763031040682
   PubMed Web of Science ®Google Scholar
• Szász JA, Constantin V, Mihály I, et al. Dopamine agonists in Parkinson’s disease therapy - 15 years of experience of the neurological clinics from Tirgu Mures. A cross-sectional study. Ideggyogy Sz. 2019;72(5–6):187–193. doi:10.18071/isz.72.018731241263
   PubMedGoogle Scholar